

FIG. 2






FIG. 4












FIG. 3B



4/15








FIG. 5B

5/15



APPROVED	Q.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN	,	







FIG. 7B






FIG. 8






FIG. 9



8/15



TIME AFTER CHEMOTHERAPY (HOURS)

FIG. 10A




FIG. 10B

APPROVED Q.G. FIG.

BY CLASS SUBCLASS

DRAFTSMAN

9/15





FIG. 11



10/15




FIG. 12A




FIG. 12B

APPROVED Q.G. FIG.


BY CLASS SUBCLASS

DRAFTSMAN



(-) ANTI G-CSF ABS

(+) ANTI G-CSF ABS








FIG. 14



0.40 0.35 0.30 0.25 0.20 0.15 0.1 0.05 0 CONTROL 5FU CI-IB-MECA 5FU+CI-IB-MECA FIG. 16










FIG. 17





FIG. 18



14/15




FIG. 19A




FIG. 19B

APPROVED @.G. FIG.

BY CLASS SUBCLASS

DRAFTSMAN

09/700751

15/15

